Connect with others who understand.

sign up log in
Resources
About MyMSTeam

Connect with others who understand.

sign up log in
Resources
About MyMSTeam
Real members of MyMSTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.

Ocrelizumab

Ocrelizumab

Has anyone consulted their neurologists ab8ut Ocrelizumab or is anyone on a trial?I heard that it's a sister med of rituxan.

posted March 4, 2017 (edited)
A MyMSTeam Member

I was on copaxone for two years and I had a relapse late October and I'm going to start the trial wish me luck and I'll also keep you guys informed,.

posted March 4, 2017
A MyMSTeam Member

“We strongly believe in the potential of OCREVUS as a new therapeutic option for both people with relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS)," said Sandra Horning, M.D., Chief Medical Officer and Head of Global Product Development. “We are working closely with the FDA during their review and committed to bringing this innovative medicine to the over 400,000 people with MS in the US living with this disabling disease as quickly as possible.”
OCREVUS™ is the proprietary name submitted to global regulatory authorities for the investigational medicine ocrelizumab.

OCREVUS is an investigational, humanised monoclonal antibody designed to selectively target CD20-positive B cells. CD20-positive B cells are a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage, which can result in disability in people with MS. Based on preclinical studies, OCREVUS binds to CD20 cell surface proteins expressed on certain B cells, but not on stem cells or plasma cells, and therefore important functions of the immune system may be preserved.
The Phase III clinical development programme for OCREVUS (ORCHESTRA) includes three studies: OPERA I, OPERA II and ORATORIO. OPERA I and OPERA II are identical Phase III, randomised, double-blind, double-dummy, global multi-centre studies that evaluated the efficacy and safety of OCREVUS (600 mg administered by intravenous infusion every six months) compared with interferon beta-1a (44 mcg administered by subcutaneous injection three times per week) in 1,656 people with relapsing forms of MS (i.e., relapsing-remitting MS and secondary-progressive MS with relapses).1 ORATORIO is a Phase III, randomised, double-blind, global multi-centre study that evaluated the efficacy and safety of OCREVUS (600 mg administered by intravenous infusion every six months; given as two 300 mg infusions two weeks apart) compared with placebo in 732 people with primary progressive MS (PPMS).2

posted May 28, 2017
A MyMSTeam Member

Im on copaxone now just took my shot

posted March 5, 2017
A MyMSTeam Member

Good luck Luckiistar !!!!

posted March 18, 2017

Related content

View all
Has Any Treatment Been Approved Yet For Primary Progressive Ms?
A MyMSTeam Member asked a question 💭
Is Anyone On Rituxan? Has It Improved Symptoms?
A MyMSTeam Member asked a question 💭
Is There Any New Treatments For Secondary Progressive
A MyMSTeam Member asked a question 💭
MULTIPLE SCLEROSIS
NEWS
Two MS Drugs May Increase Risks for Breakthrough COVID-19 Infections

Two MS Drugs May Increase Risks for Breakthrough COVID-19 Infections

A MyMSTeam Member

The vaccine made me have debilitating symptoms and may have exasperated my MS

posted September 29

4 1

All updates must be accompanied by text or a picture.
Already a Member? Log in